Unknown

Dataset Information

0

Vascular smooth muscle cell-selective peroxisome proliferator-activated receptor-gamma deletion leads to hypotension.


ABSTRACT: Peroxisome proliferator-activated receptor-gamma (PPARgamma) agonists are commonly used to treat diabetes, although their PPARgamma-dependent effects transcend their role as insulin sensitizers. Thiazolidinediones lower blood pressure (BP) in diabetic patients, whereas results from conventional/tissue-specific PPARgamma experimental models suggest an important pleiotropic role for PPARgamma in BP control. Little evidence is available on the molecular mechanisms underlying the role of vascular smooth muscle cell-specific PPARgamma in basal vascular tone.We show that vascular smooth muscle cell-selective deletion of PPARgamma impairs vasoactivity with an overall reduction in BP. Aortic contraction in response to norepinephrine is reduced and vasorelaxation is enhanced in response to beta-adrenergic receptor (beta-AdR) agonists in vitro. Similarly, vascular smooth muscle cell-selective PPARgamma knockout mice display a biphasic response to norepinephrine in BP, reversible on administration of beta-AdR blocker, and enhanced BP reduction on treatment with beta-AdR agonists. Consistent with enhanced beta2-AdR responsiveness, we found that the absence of PPARgamma in vascular smooth muscle cells increased beta2-AdR expression, possibly leading to the hypotensive phenotype during the rest phase.These data uncovered the beta2-AdR as a novel target of PPARgamma transcriptional repression in vascular smooth muscle cells and indicate that PPARgamma regulation of beta2-adrenergic signaling is important in the modulation of BP.

SUBMITTER: Chang L 

PROVIDER: S-EPMC2829656 | biostudies-literature | 2009 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Vascular smooth muscle cell-selective peroxisome proliferator-activated receptor-gamma deletion leads to hypotension.

Chang Lin L   Villacorta Luis L   Zhang Jifeng J   Garcia-Barrio Minerva T MT   Yang Kun K   Hamblin Milton M   Whitesall Steven E SE   D'Alecy Louis G LG   Chen Y Eugene YE  

Circulation 20090413 16


<h4>Background</h4>Peroxisome proliferator-activated receptor-gamma (PPARgamma) agonists are commonly used to treat diabetes, although their PPARgamma-dependent effects transcend their role as insulin sensitizers. Thiazolidinediones lower blood pressure (BP) in diabetic patients, whereas results from conventional/tissue-specific PPARgamma experimental models suggest an important pleiotropic role for PPARgamma in BP control. Little evidence is available on the molecular mechanisms underlying the  ...[more]

Similar Datasets

| S-EPMC2949502 | biostudies-literature
| S-EPMC2642522 | biostudies-literature
| S-EPMC6494719 | biostudies-literature
| S-EPMC2781385 | biostudies-literature
| S-EPMC3077093 | biostudies-other
| S-EPMC3632601 | biostudies-literature
| S-EPMC4599849 | biostudies-literature
| S-EPMC2907524 | biostudies-literature
| S-EPMC3911778 | biostudies-literature
| S-EPMC5724174 | biostudies-literature